Shoshana Levy

Dr. Shoshana Levy


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2014 in Viruses
Verified
Journal Article
Open access
PDF file
LFLucie Fénéant
Lucie Fénéant
SLShoshana Levy
Shoshana Levy
LCLaurence Cocquerel
Laurence Cocquerel
Hepatitis C Virus (HCV) infection is a global public health problem affecting over 160 million individuals worldwide. Its symptoms include chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. HCV is an enveloped RNA virus mainly targeting liver cells and for which the initiation of infection occurs through a complex multistep process involving a series of specific cellular entry factors. This process is likely mediated through the formation of a tightly orchestrated complex of HCV entry factors at the plasma membrane. Among HCV entry factors, the tetraspanin CD81 is one of the best characterized and it is undoubtedly a key player in the HCV lifecycle. In this review, we detail the current knowledge on the involvement of CD81 in the HCV lifecycle, as well as in the immune response to HCV infection.

13 February 2014 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
SLShoshana Levy
Shoshana Levy

1 November 2015 in Cancer Research
Verified
Journal Article
Open access
PDF file
FVFelipe Vences-Catalán
Felipe Vences-Catalán
RRRanjani Rajapaksa
Ranjani Rajapaksa
MSMinu K. Srivastava
Minu K. Srivastava
AMAurelien Marabelle
Aurelien Marabelle
CKChiung-Chi Kuo
Chiung-Chi Kuo
SLShoshana Levy
Shoshana Levy
Tumor cells counteract innate and adaptive antitumor immune responses by recruiting regulatory T cells (Treg) and innate myeloid-derived suppressor cells (MDSC), which facilitate immune escape and metastatic dissemination. Here we report a role in these recruitment processes for CD81, a member of the tetraspanin family of proteins that have been implicated previously in cancer progression. We found that genetic deficiency in CD81 reduced tumor growth and metastasis in two genetic mouse backgrounds and multiple tumor models. Mechanistic investigations revealed that CD81 was not required for normal development of Treg and MDSC but was essential for immunosuppressive functions. Notably, adoptive transfer of wild-type Treg into CD81-deficient mice was sufficient to promote tumor growth and metastasis. Our findings suggested that CD81 modulates adaptive and innate immune responses, warranting further investigation of CD81 in immunomodulation in cancer and its progression. Cancer Res; 75(21); 4517–26. ©2015 AACR.

7 June 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
FVFelipe Vences-Catalán
Felipe Vences-Catalán
RRRanjani Rajapaksa
Ranjani Rajapaksa
CKChiung-Chi Kuo
Chiung-Chi Kuo
CMCaitlyn L. Miller
Caitlyn L. Miller
ALAnderson Lee
Anderson Lee
SLShoshana Levy
Shoshana Levy
Significance: CD81 belongs to the evolutionary conserved tetraspanin family of proteins that form specialized membranal platforms that facilitate a vast array of cellular processes. However, little is known about the consequences of these molecular interactions under normal or pathological conditions. Tetraspanins have no known natural ligands, but ligation by some antibodies induces functional consequences. Here we show that engagement of CD81 with 5A6 halts tumor invasion in vitro and reduces breast cancer metastasis in vivo. Altogether, these finding highlight the role of CD81 in cancer progression.

13 April 2017 in Biochemical Society Transactions
Verified
Journal Article
Closed access
PDF file
FVFelipe Vences-Catalán
Felipe Vences-Catalán
CDCaroline Duault
Caroline Duault
CKChiung-Chi Kuo
Chiung-Chi Kuo
RRRanjani Rajapaksa
Ranjani Rajapaksa
RLRonald Levy
Ronald Levy
SLShoshana Levy
Shoshana Levy
CD81 participates in a variety of important cellular processes such as membrane organization, protein trafficking, cellular fusion and cell–cell interactions. In the immune system, CD81 regulates immune synapse, receptor clustering and signaling; it also mediates adaptive and innate immune suppression. CD81 is a gateway in hepatocytes for pathogens such as hepatitis C virus and Plasmodium; it also confers susceptibility to Listeria infection. These diverse biological roles are due to the tendency of CD81 to associate with other tetraspanins and with cell-specific partner proteins, which provide the cells with a signaling platform. CD81 has also been shown to regulate cell migration and invasion, and has therefore been implicated in cancer progression. Indeed, we have recently shown that CD81 contributes to tumor growth and metastasis. CD81 is expressed in most types of cancer, including breast, lung, prostate, melanoma, brain cancer and lymphoma, and the overexpression or down-regulation of this molecule has been correlated with either good or bad prognosis. Here, we discuss the role of CD81 in cancer and its potential therapeutic use as a tumor target.

1 September 2009 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
GCGreg P. Coffey
Greg P. Coffey
RRRanjani Rajapaksa
Ranjani Rajapaksa
RLRaymond Liu
Raymond Liu
OSOrr Sharpe
Orr Sharpe
CKChiung-Chi Kuo
Chiung-Chi Kuo
SLShoshana Levy
Shoshana Levy
CD81 is a tetraspanin family member involved in diverse cellular interactions in the immune and nervous systems and in cell fusion events. However, the mechanism of action of CD81 and of other tetraspanins has not been defined. We reasoned that identifying signaling molecules downstream of CD81 would provide mechanistic clues. We engaged CD81 on the surface of B-lymphocytes and identified the induced tyrosine-phosphorylated proteins by mass spectrometry. This analysis showed that the most prominent tyrosine phosphorylated protein was ezrin, an actin-binding protein and a member of the ezrin-radixin-moesin family. We also found that CD81 engagement induces spleen tyrosine kinase (Syk) and that Syk was involved in tyrosine phosphorylation of ezrin. After engagement of CD81, it colocalized with ezrin and F-actin, and this association was disrupted when Syk activation was blocked. Taken together, these studies suggest a model in which CD81 interfaces between the plasma membrane and the cytoskeleton by activating Syk, mobilizing ezrin, and recruiting F-actin to facilitate cytoskeletal reorganization and cell signaling. This mechanism might explain the pleiotropic effects induced in response to stimulation of cells by anti-CD81 antibodies or by the hepatitis C virus, which uses this molecule as its key receptor.